Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Recent GLP-1 Weight Loss Drug Market Developments: Novo Nordisk, Eli Lilly, Amgen, and FDA Lead 20252026 April 2026: Eli Lilly submitted the orforglipron New Drug Application to the FDA for obesity treatment, reporting 14.7% body weight reduction in the ATTAIN-WEIGHT1 Phase 3 trial at the 45mg dose the first oral small molecule GLP-1 receptor agonist NDA submission for dedicated obesity pharmacological treatment in the United States
Measurement: 1.0 mg equals 6 units, 1.5 mg equals 9 units, and 2.0 mg equals 12 units
Zhao, L., Tang, J., & Kim, S
In the first 30 days of starting a GLP-1 medication, most patients begin to notice subtle but meaningful changes in appetite, energy levels, and digestion
Research suggests that only about 4 to 8 serious complications occur for every 10,000 screening procedures performed
